
This study investigates Down syndrome (DS) patients with B-cell acute lymphoblastic leukemia (B-ALL) enrolled in Children's Oncology Group trials from 2003 to 2019. DS patients, numbering 743, experienced higher rates of minimal residual disease (MRD) and poorer 5-year event-free survival and overall survival compared to non-DS patients. Multivariable analysis identified risk factors for inferior outcomes in DS patients. They exhibited increased relapse rates and treatment-related mortality, emphasizing the need for less-toxic therapeutic strategies to enhance outcomes.
Like
Save
Share